Objectives: This systematic review and meta-analysis of randomized controlled trials (RCTs) compared the clinical efficacy and safety of reduced-dose prasugrel (loading dose: 20 mg; daily maintenance dose: 3.75 mg) and clopidogrel in patients undergoing percutaneous coronary intervention (PCI). Methods: PubMed, Embase, and the Cochrane Library database were searched for relevant articles from inception to March 8, 2021. Only RCTs that compared the clinical efficacy and safety of reduced-dose prasugrel and clopidogrel treatment in adult patients undergoing PCI were included. The primary outcome was the risk of major cardiovascular events (MACEs). Results: Four RCTs involving 2464 patients were included. The overall risk of MACEs was 8.3% (102/1235) in the study group (reduced-dose prasugrel) and 9.8% (121/1229) in the control group (clopidogrel). No significant difference was observed in the risk of MACEs between the study and control groups (risk ratio: 0.84, 95% confidence interval: 0.65-1.08, I 2 = 0%). In addition, cardiovascular-related death, all-cause death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and stent thrombosis did not differ significantly between the two groups. Apart from a higher risk of minor bleeding in the study group, reduced-dose prasugrel had a similar bleeding risk to clopidogrel. Conclusions: The clinical efficacy of reduced-dose prasugrel is comparable to that of clopidogrel; however, the risk of minor bleeding should be considered when prescribing this regimen for patients undergoing PCI.
Objectives: This systematic review and meta-analysis of randomized controlled trials (RCTs) compared the clinical efficacy and safety of reduced-dose prasugrel (loading dose: 20 mg; daily maintenance dose: 3.75 mg) and clopidogrel in patients undergoing percutaneous coronary intervention (PCI). Methods: PubMed, Embase, and the Cochrane Library database were searched for relevant articles from inception to March 8, 2021. Only RCTs that compared the clinical efficacy and safety of reduced-dose prasugrel and clopidogrel treatment in adult patients undergoing PCI were included. The primary outcome was the risk of major cardiovascular events (MACEs). Results: Four RCTs involving 2464 patients were included. The overall risk of MACEs was 8.3% (102/1235) in the study group (reduced-dose prasugrel) and 9.8% (121/1229) in the control group (clopidogrel). No significant difference was observed in the risk of MACEs between the study and control groups (risk ratio: 0.84, 95% confidence interval: 0.65-1.08, I 2 = 0%). In addition, cardiovascular-related death, all-cause death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and stent thrombosis did not differ significantly between the two groups. Apart from a higher risk of minor bleeding in the study group, reduced-dose prasugrel had a similar bleeding risk to clopidogrel. Conclusions: The clinical efficacy of reduced-dose prasugrel is comparable to that of clopidogrel; however, the risk of minor bleeding should be considered when prescribing this regimen for patients undergoing PCI.
Entities:
Keywords:
Bleeding; Clopidogrel; Coronary artery disease; Major cardiovascular event; Prasugrel
Authors: Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith Journal: Circulation Date: 2016-03-29 Impact factor: 29.690
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Matthew T Roe; Paul W Armstrong; Keith A A Fox; Harvey D White; Dorairaj Prabhakaran; Shaun G Goodman; Jan H Cornel; Deepak L Bhatt; Peter Clemmensen; Felipe Martinez; Diego Ardissino; Jose C Nicolau; William E Boden; Paul A Gurbel; Witold Ruzyllo; Anthony J Dalby; Darren K McGuire; Jose L Leiva-Pons; Alexander Parkhomenko; Shmuel Gottlieb; Gracita O Topacio; Christian Hamm; Gregory Pavlides; Assen R Goudev; Ali Oto; Chuen-Den Tseng; Bela Merkely; Vladimir Gasparovic; Ramon Corbalan; Mircea Cinteză; R Craig McLendon; Kenneth J Winters; Eileen B Brown; Yuliya Lokhnygina; Philip E Aylward; Kurt Huber; Judith S Hochman; E Magnus Ohman Journal: N Engl J Med Date: 2012-08-25 Impact factor: 91.245